Evidence map›Paper›PMID 33367606›Full record

ReviewThe journals of gerontology. Series A, Biological sciences and medical sciences2022

Age, Multiple Chronic Conditions, and COVID-19: A Literature Review.

Mayra Tisminetzky, Christopher Delude, Tara Hebert, Catherine Carr, Robert J Goldberg, Jerry H Gurwitz

Open access · bronzeAbstract readReview
In one paragraph

Review in The journals of gerontology. Series A, Biological sciences and medical sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 3 pooled it
1.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 3 syntheses or guidelines pooled it, 105 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Effects ofNutrients · 2022
    Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Mayra TisminetzkyMeyers Primary Care Institute, Worcester, Massachusetts, USA.ORCID 0000-0002-8557-2029
Christopher DeludeMeyers Primary Care Institute, Worcester, Massachusetts, USA.
Tara HebertMeyers Primary Care Institute, Worcester, Massachusetts, USA.
Catherine CarrLamar Soutter Library, University of Massachusetts Medical School, Worcester, USA.
Robert J GoldbergMeyers Primary Care Institute, Worcester, Massachusetts, USA.
Jerry H GurwitzMeyers Primary Care Institute, Worcester, Massachusetts, USA.
University of Massachusetts Chan Medical School · US

Funding

Preparing For What Is Next With Aducanumab In Real World SettingsR33AG057806 · NIA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Christopher Barrett Bowling, Ana Roman Quinones · 2018 to 2026
$9.0M
WORCHESTER HEART ATTACK COMMUNITY SURVEILLANCE STUDYR01HL035434 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI GOLDBERG, ROBERT JOEL · 1987 to 2014
$7.4M
TRACE-COREU01HL105268 · NHLBI · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI KIEFE, CATARINA I. · 2010 to 2013
$5.8M
Multimorbidity and Treatment-Related Outcomes in Older Heart Failure PatientsR01AG062630 · NIA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI TISMINETZKY, MAYRA S. · 2019 to 2022
$2.4M
NHLBI NIH HHS R01 HL035434NHLBI NIH HHS U01 HL105268NIA NIH HHS R01 AG062630NIA NIH HHS R33 AG057806
6 · The paper itself

Abstract

backgroundVarious patient demographic and clinical characteristics have been associated with poor outcomes for individuals with coronavirus disease 2019 (COVID-19). To describe the importance of age and chronic conditions in predicting COVID-19-related outcomes.

methodsSearch strategies were conducted in PubMed/MEDLINE. Daily alerts were created.

resultsA total of 28 studies met our inclusion criteria. Studies varied broadly in sample size (n = 21 to more than 17,000,000). Participants' mean age ranged from 48 years to 80 years, and the proportion of male participants ranged from 44% to 82%. The most prevalent underlying conditions in patients with COVID-19 were hypertension (range: 15%-69%), diabetes (8%-40%), cardiovascular disease (CVD) (4%-61%), chronic pulmonary disease (1%-33%), and chronic kidney disease (range 1%-48%). These conditions were each associated with an increased in-hospital case fatality rate (CFR) ranging from 1% to 56%. Overall, older adults have a substantially higher case fatality rate (CFR) as compared to younger individuals affected by COVID-19 (42% for those <65 vs 65% > 65 years). Only one study examined the association of chronic conditions and the risk of dying across different age groups; their findings suggested similar trends of increased risk in those < 65 years and those > 65 years as compared to those without these conditions.

conclusionsThere has been a traditional, single-condition approach to consideration of how chronic conditions and advancing age relate to COVID-19 outcomes. A more complete picture of the impact of burden of multimorbidity and advancing patient age is needed.

Indexed as

COVID-19Diabetes MellitusMultiple Chronic ConditionsAgedHumansMaleMultimorbiditySARS-CoV-2COVID-19EpidemiologyMultimorbidity

Identifiers

PMID33367606
PMCPMC7799222
OpenAlexW3116557576

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.